Litigation Details for Celgene Corporation v. Aurobindo Pharma Limited (D. Del. 2018)

Celgene Corporation v. Aurobindo Pharma Limited (D. Del. 2018)

Docket		Date Filed	2018-07-06
Court	District Court, D. Delaware	Date Terminated	2018-10-04
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	6,962,940; 7,208,516; 7,427,638; 7,659,302; 7,893,101; 8,455,536; 8,802,717; 9,018,243; 9,872,854
Link to Docket	External link to docket

Details for Celgene Corporation v. Aurobindo Pharma Limited (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-06				External link to document
2018-07-06	1	Complaint	United States Patent Nos. 6,962,940 (“the ’940 Patent”), 7,208,516 (“the ’516 Patent”), 7,427,638 (… (“the ’638 Patent”), 7,659,302 (“the ’302 Patent”), 7,893,101 (“the ’101 Patent”), 8,455,536 (“the ’… ’536 Patent”), 8,802,717 (“the ’717 Patent”), 9,018,243 (“the ’243 Patent”), and 9,872,854 (“the ’854… This is a civil action for patent infringement arising under the patent laws of the United States, …854 Patent”) (collectively, “the Patents-in-Suit”). Case 1:18-cv-01005-RGA Document 1 Filed 07/06/18	External link to document
2018-07-06	7		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,962,940 B2; 7,208,516 B2; 7,427,638…2018 4 October 2018 1:18-cv-01005 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Celgene Corporation v. Aurobindo Pharma Limited, 1:18-cv-01005: Litigation Summary and Patent Analysis

Last updated: August 3, 2026

Celgene Corporation sued Aurobindo Pharma Limited in the U.S. District Court for the District of Delaware after Aurobindo filed an abbreviated new drug application for generic lenalidomide capsules, the active ingredient in Revlimid. The case was a Hatch-Waxman patent dispute under 35 U.S.C. § 271(e)(2). The public record indicates that the parties resolved the matter without a merits judgment, and the action was dismissed pursuant to settlement. The settlement terms and any authorized launch date were not publicly disclosed in the court docket.

What drug and ANDA were at issue in Celgene v. Aurobindo?

The dispute concerned Revlimid, Celgene’s branded lenalidomide product.

Item	Details
Brand drug	Revlimid
Active ingredient	Lenalidomide
Innovator	Celgene Corporation
Generic applicant	Aurobindo Pharma Limited
Dosage form	Oral capsules
Strengths generally associated with the ANDA dispute	5 mg, 10 mg, 15 mg and 25 mg
FDA pathway	ANDA
Legal framework	Hatch-Waxman Act; 35 U.S.C. § 271(e)(2)
Court	U.S. District Court for the District of Delaware
Civil action	1:18-cv-01005
Patent dispute type	Paragraph IV patent litigation

Aurobindo’s ANDA filing required certification regarding patents listed for Revlimid in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. Celgene’s lawsuit triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the statutory rules governing the timing and effect of the litigation.

What patents protected Revlimid in the Aurobindo litigation?

Celgene’s Revlimid patent estate included patents directed to lenalidomide compositions, polymorphic forms, pharmaceutical formulations and methods of treating hematologic cancers. The specific patents asserted against Aurobindo must be determined from the complaint, amended pleadings and claim-construction record rather than from the product’s full historical Orange Book listing.

The patent estate was broader than a single compound patent. That distinction was commercially important because later-filed patents could maintain litigation leverage after earlier patents approached expiration.

Core patent categories

Patent category	Typical protection	Relevance to generic entry
Active-ingredient or compound patents	Lenalidomide and related chemical structures	High, if valid and unexpired
Solid-state or polymorph patents	Specific crystalline or physical forms	Depends on the ANDA’s formulation and characterization
Formulation patents	Capsule composition, excipients or dosage presentation	Can create product-specific infringement risk
Method-of-use patents	Treatment of multiple myeloma, myelodysplastic syndromes or other diseases	May support a restricted-label or skinny-label strategy
Risk-management patents and regulatory controls	Distribution or prescribing controls associated with Revlimid	Usually create compliance and commercial barriers rather than ordinary product-formulation exclusivity

Celgene’s commercially relevant protection for Revlimid also included patents that were not necessarily all asserted in every ANDA case. Patent-by-patent analysis requires separating patents listed in the Orange Book from patents cited in the complaint and from patents later added through continuation or divisional prosecution.

When did the Celgene v. Aurobindo litigation begin?

The case was filed in 2018 under Civil Action No. 1:18-cv-01005 in Delaware. The complaint followed Aurobindo’s ANDA filing and Paragraph IV certification.

The standard Hatch-Waxman sequence was:

1. Aurobindo submitted an ANDA seeking FDA approval for generic lenalidomide capsules.
2. Aurobindo provided Celgene with a Paragraph IV notice.
3. Celgene filed an infringement action under § 271(e)(2).
4. The lawsuit imposed or maintained a statutory approval stay while the patent claims were litigated or resolved.
5. The parties settled before a public trial or final judgment on validity and infringement.
6. The case was dismissed under the settlement framework.

The docket does not provide a public adjudication holding that the asserted patents were valid, infringed or enforceable. It therefore should not be treated as precedent on the merits.

What was the litigation outcome?

The case ended through settlement and dismissal rather than a reported decision after trial.

Issue	Publicly supportable conclusion
Liability finding	None reported
Patent invalidity ruling	None reported
Infringement ruling	None reported
Unenforceability ruling	None reported
Settlement	Yes, reflected in the case disposition
Settlement terms	Not fully disclosed in the public docket
Authorized generic launch date	Not established by a public merits opinion
Ongoing case	No, the action was dismissed

A settlement dismissal generally means that the parties resolved the dispute contractually. It does not establish that Celgene’s patent claims would have survived an invalidity challenge, nor does it establish that Aurobindo’s ANDA product infringed.

Did Aurobindo win or lose the patent case?

Neither side received a merits judgment. Celgene obtained a settlement that ended the litigation and preserved negotiated control over generic entry. Aurobindo avoided the cost and uncertainty of trial and obtained whatever launch rights or other commercial terms were provided by the confidential agreement.

The practical result was therefore commercial rather than precedential. The important questions are the settlement’s authorized launch date, any volume limitations, and whether the agreement included an authorized generic arrangement. Those terms were not fully disclosed in the public record for this action.

What was the FDA and Orange Book status of Revlimid?

Revlimid was FDA-approved as an oral lenalidomide product for multiple indications, including multiple myeloma and myelodysplastic syndromes. The product was subject to restricted-distribution and risk-management requirements because lenalidomide is structurally related to thalidomide and carries serious embryo-fetal toxicity risks.

The Orange Book listing gave Celgene a basis to bring a statutory patent action after the Paragraph IV certification. The listing did not itself guarantee patent validity. An Orange Book patent can be challenged through Paragraph IV litigation, and the FDA’s regulatory approval process does not determine whether the patent is legally enforceable.

Regulatory implications for Aurobindo

An approved generic lenalidomide product would need to address:

• Bioequivalence to the relevant Revlimid reference product.
• Strength-specific labeling.
• Capsule composition and manufacturing controls.
• The applicable restricted-distribution requirements.
• Any method-of-use exclusions needed to avoid patented indications.
• Supply-chain and pharmacy controls associated with lenalidomide.

FDA approval and commercial launch were separate events. Aurobindo could not necessarily launch immediately after receiving approval if the settlement imposed a later entry date or other contractual restrictions.

What generic-entry risks existed for Celgene?

The principal risk was loss of Revlimid pricing power after the first meaningful generic launch. Revlimid generated approximately $9.7 billion in worldwide net sales for Celgene in 2018, making generic entry a material revenue event for the company (Celgene Corporation, 2019).

The risk profile had several components:

Early-entry risk

A settlement allowing Aurobindo to launch before the final expiration of the full patent estate could reduce the period of complete monopoly protection. Even a controlled launch could affect contracting, payer negotiations and pharmacy substitution.

Multi-entrant erosion

Aurobindo was one of several generic companies pursuing lenalidomide approval. Multiple settlements could create staggered entry dates. Once more than one generic manufacturer entered, price erosion and market-share migration would likely accelerate.

Formulation and polymorph risk

If Aurobindo’s ANDA used a formulation or solid form covered by a valid patent, Celgene could retain a stronger infringement position. If the ANDA avoided those limitations, Celgene would have to rely on broader composition or method claims.

Method-of-use risk

Revlimid had multiple indications. A generic company could seek approval for unpatented uses while omitting patented indications from its label. That strategy can reduce, but not eliminate, litigation exposure. Dispensing practices, physician prescribing and product promotion can create additional legal issues.

Manufacturing risk

Lenalidomide manufacturing requires control of chemical purity, solid-state properties, dosage uniformity and contamination risks. Manufacturing patents and process know-how could delay a generic even where the product claims were vulnerable. Process patents generally have less direct Orange Book leverage than patents covering the approved drug product, but they can increase operational and litigation risk.

How strong was Celgene’s patent estate against Aurobindo?

Celgene’s estate was commercially strong because it combined multiple patent categories with regulatory exclusivity and a high-value product. Its strength was not equivalent across all patents.

Strength factor	Assessment
Revenue exposure	Very high
Product importance	Core Celgene asset
Number of potential patent layers	Broad
Compound-level protection	Strongest where valid and unexpired
Formulation protection	Dependent on Aurobindo’s actual capsule composition
Method-of-use protection	Vulnerable to indication carve-outs
Litigation leverage	High before settlement
Public merits validation in this case	None
Post-settlement certainty	Dependent on confidential commercial terms

The absence of a merits ruling limits conclusions about ultimate patent strength. The settlement shows that the estate had sufficient commercial value to support negotiated resolution, but it does not prove that each asserted claim was enforceable.

What patent expiration dates affected Revlimid generic entry?

Revlimid’s exclusivity timeline was governed by a group of patents and regulatory exclusivities rather than one universally controlling expiration date. Patent expiration can also vary based on patent-term adjustment, patent-term extension, terminal disclaimers and the specific claim asserted.

A reliable expiration analysis must be performed patent by patent using the issued patent, prosecution history, PTA calculation, any PTE certificate and the Orange Book listing. The public disposition of 1:18-cv-01005 does not establish one definitive generic-entry date.

The later commercial availability of generic lenalidomide in the United States indicates that negotiated and regulatory barriers eventually permitted generic entry. That market event should not be attributed to a merits victory by Aurobindo in this case.

Were biosimilars a risk in this litigation?

No. Lenalidomide is a synthetic small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA for a generic drug under the Hatch-Waxman framework, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The correct competitive risks were:

• Paragraph IV ANDA challenges.
• Authorized generic competition.
• Staggered generic launches.
• Label carve-outs.
• Formulation design-arounds.
• Contracting and payer substitution.

Biosimilar interchangeability and reference-product exclusivity rules were not central to this case.

Which companies challenged Revlimid patents?

Celgene faced multiple generic challenges to Revlimid from companies seeking ANDA approval. Publicly reported Revlimid patent litigation involved major generic manufacturers, including Teva, Dr. Reddy’s Laboratories, Natco, Cipla and Aurobindo, among others.

Each case had to be analyzed separately. A settlement with one applicant did not automatically establish the launch rights of another applicant. The commercial impact depended on:

• The negotiated entry date.
• Whether the applicant received limited early-launch rights.
• The number of entrants at that time.
• Any volume caps.
• The presence of an authorized generic.
• The scope of the applicant’s approved label.

What does the case mean for generic launch scenarios?

The most likely commercial scenarios were controlled entry under settlement, followed by broader entry after the relevant patent barriers expired or were resolved.

Scenario	Commercial effect
No early launch	Celgene retains full Revlimid economics until the negotiated date
Limited-volume settlement launch	Partial erosion with controlled supply
Single generic launch	Moderate initial price and share pressure
Multiple generic launches	Faster price erosion and payer substitution
Skinny-label launch	Reduced infringement exposure but narrower indication coverage
Authorized generic arrangement	Potentially greater control over price and channel economics

Because the settlement terms were not public, the docket alone cannot establish which scenario applied to Aurobindo.

Key Takeaways

• Celgene v. Aurobindo, 1:18-cv-01005, was a Hatch-Waxman Paragraph IV case involving generic lenalidomide capsules.
• Celgene asserted Revlimid-related patent rights after Aurobindo filed an ANDA.
• The case ended by settlement and dismissal without a public decision on patent validity, infringement or enforceability.
• The settlement terms and Aurobindo’s precise authorized launch rights were not fully disclosed in the public docket.
• Revlimid’s patent protection included multiple layers covering the active ingredient, formulations, solid-state properties and methods of use.
• The relevant competitive threat was generic entry, not biosimilar substitution.
• Revlimid’s approximately $9.7 billion 2018 sales made the litigation commercially material.
• A case dismissal after settlement should not be characterized as either a Celgene merits victory or an Aurobindo patent victory.

FAQs

Did Aurobindo receive FDA approval for generic Revlimid?

An ANDA filing and patent settlement do not by themselves establish the date or conditions of FDA approval. The litigation record confirms the patent dispute, not the complete regulatory history of Aurobindo’s ANDA.

Did Celgene sue Aurobindo over all Revlimid patents?

Not necessarily. The relevant claims are the patents identified in the complaint and subsequent pleadings. Revlimid had a broader historical Orange Book and continuation patent estate than any single lawsuit necessarily asserted.

Was there a trial in Celgene v. Aurobindo?

No public trial or final merits decision is reflected in the case disposition. The action was resolved through settlement and dismissed.

Could Aurobindo launch with a skinny label?

A skinny-label strategy could reduce infringement exposure for patented indications, but it would depend on the ANDA labeling, the asserted method claims and the statutory requirements governing omission of protected uses.

Does this case determine when all generic lenalidomide could enter?

No. Aurobindo’s settlement was specific to that applicant. Other ANDA applicants could have different settlement terms, litigation outcomes and launch dates.

References

1. Celgene Corporation v. Aurobindo Pharma Limited, No. 1:18-cv-01005, U.S. District Court for the District of Delaware, docket records.

2. Celgene Corporation. (2019). 2018 annual report. U.S. Securities and Exchange Commission.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

5. 21 U.S.C. § 355. (2024). Applications for FDA approval to market new drugs.

6. 35 U.S.C. § 271(e)(2). (2024). Infringement based on submission of an ANDA.